ImmunoPrecise Antibodies Leverages Proprietary Technology and Expertise to Create Talem Therapeutics

VICTORIA, April 4, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announces it has formed a wholly-owned, Cambridge, Massachusetts-based subsidiary, Talem Therapeutics (Talem). Talem is focused on the discovery and development of next-generation, fully-human, monoclonal therapeutic antibodies targeting neurology, immuno-oncology, gastroenterology, inflammation, and rare/specialty diseases. Using proprietary antibody discovery platforms and innovative technologies, Talem will be producing a rich pipeline of high quality and distinct antibodies.

The demand for safe, therapeutic, monoclonal antibody (mAb) candidates with more complex target product profiles is driving a need for more robust discoveries. Talem was founded to expedite the high-powered discovery and development of custom therapeutics produced as both internal assets as well as in response to partnership requests with large pharma.

Talem Therapeutics’ strategy is to develop on-demand and in-house antibodies through pre-clinical stage prior to licensing for clinical partners. The speed and adaptability of IPAs platforms enables Talem to quickly respond to targets based on years of experience and expertise in the antibody discovery sector. Along with the designated pre-clinical programs, Talem is also engaging in negotiations on joint research and development (R&D) programs with numerous pharmaceutical companies.

About Talem Therapeutics

Talem Therapeutics ( is an international biopharmaceutical company focused on the discovery and development of new antibodies originating from IPA’s innovative and proprietary technologies and Structure-Based Drug Design platform capabilities. Talem will focus on a broad pipeline of partnered and in-house drug candidates in multiple therapeutic areas including, but not limited to, neurology, immuno-oncology, gastroenterology, inflammation, and rare/specialty diseases.

About ImmunoPrecise Antibodies Ltd.

ImmunoPrecise is a full-service, therapeutic antibody discovery company focused on the next generation of antibody discovery, to deliver the most therapeutically-relevant antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials.

ImmunoPrecise operates from state-of-the-art laboratory facilities located at the Vancouver Island Technology Park in Victoria, British Columbia, in collaboration with its wholly-owned subsidiary operations at U-Protein Express B.V., in the Life Science Incubator, Utrecht, and ModiQuest Research, Oss, both in the Netherlands. The Company operates globally to offer antibody services from target analysis to pre-clinical studies.

The services offered to clients include antibody discovery against a broad spectrum of antigens, including challenging targets. Amongst these services, the Company offers hybridoma production, B cell services, and a variety of phage display platforms. The Company also provides a broad range of supporting services including immunologically-based assays, recombinant protein manufacturing, humanization, optimization, stable cell line development, and advanced solutions to challenges faced by clients in antibody-related research and development. The antibodies produced by ImmunoPrecise target a wide variety of therapeutic, diagnostic and research applications.

Forward Looking Information

This news release contains statements that, to the extent they are not recitations of historical fact, may constitute “forward-looking statements” within the meaning of applicable Canadian securities laws. The Company uses words such as “may”, “would”, “could”, “will”, “likely”, “expect”, “believe”, “intend” and similar expressions to identify forward-looking statements. Any such forward-looking statements are based on assumptions and analyses made by ImmunoPrecise in light of its experience and its perception of historical trends, current conditions and expected future developments. However, whether actual results and developments will conform to ImmunoPrecise’s expectations and predictions is subject to any number of risks, assumptions and uncertainties. Many factors could cause ImmunoPrecise’s actual results to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors include, among other things, actual revenues and earnings for IPA being lower than anticipated, and those risks and uncertainties described in ImmunoPrecise’sannual management discussion and analysis for the fiscal year ended April 30, 2018 which can be accessed at The “forward-looking statements” contained herein speak only as of the date of this press release and, unless required by applicable law, ImmunoPrecise undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE ImmunoPrecise Antibodies Ltd.

For further information:

For investor relations please contact:

Frederick Chabot, Phone: 1-438-863-7071, Email:, Contact Financial Corp., 1450 – 701 West Georgia St., Vancouver, BC V7Y 1G5